Hanmi Pharmaceutical has launched a QR code-based electronic label (e-label) service, replacing paper inserts and advancing the digital transformation of drug information.
On July 21, Hanmi announced that it has initially applied the e-label service to five products, including Yubaktam Injection 750mg, Triaxone Injection 2g Type 1 & Type 2, and Hanmi Cellotaxime Sodium Injection 2g Type 1 & Type 2. Scanning the QR code embedded in the product packaging allows users to access the latest drug information.
Drug inserts contain essential information that patients and caregivers must verify before use, but concerns have been raised about the difficulty of finding necessary details due to small print and extensive content. Additionally, the inefficiency of discarding and reprinting existing materials whenever approval details change has been a persistent issue.
To address these inconveniences, Hanmi has introduced the QR code-based e-label. This allows users to easily check key information such as efficacy, dosage, and precautions.
User convenience has also been enhanced. The text size on the screen can be adjusted in four levels, and a search function enables quick access to desired information. Key categories, including ingredient quantities, characteristics, efficacy, dosage, and precautions, are organized in accessible tabs at the top.
For users who may not be familiar with digital environments, the e-label screen includes options to download and save or print a PDF. When printing, unnecessary elements like menus and search bars are automatically excluded, ensuring that only essential information is displayed. Hanmi plans to add an e-label button to the product pages on its website in the future.
Hanmi intends to gradually expand the e-label application in consultation with the Ministry of Food and Drug Safety. This initiative is also seen as a contribution to reducing paper usage and carbon emissions, aligning with ESG (Environmental, Social, and Governance) management principles.
Ham Yoon-soo, head of the design group at Hanmi Science Communication, stated, "The e-label is a service that enhances accessibility to drug information, making it easier and more convenient to verify. We will continue to advance our digital information provision system to improve user convenience and information accessibility."
Meanwhile, Hanmi is expected to report strong performance for the second quarter of this year, influenced by receiving an upfront payment from Eli Lilly for the technology transfer of the new drug candidate 'Sonepeglutide' for short bowel syndrome.
According to consensus estimates compiled by financial information firm FnGuide, Hanmi's projected consolidated revenue for the second quarter is 438 billion won, with an operating profit of 104.2 billion won, representing increases of 21.2% and 72.3%, respectively, compared to the same period last year.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.